Sibu Rajan
Medical · Granada Hills, CANPI 1114112596
Payments from drug & device makers
Across 117 payments — averaging $74.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$5K
- Bayer$1K
- Akebia Therapeutics Inc$730
- Corcept Therapeutics$379
- Ardelyx, Inc.$272
- AstraZeneca$253
- plus $782 from 10 others
Across 8 payments — averaging $235.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$2K
What the payments were for
- Travel & lodging$5,64165%
- Food & beverage$3,04235%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 20 | $5,076 |
| Bayer | 15 | $1,191 |
| Akebia Therapeutics Inc | 28 | $730 |
| Corcept Therapeutics | 4 | $379 |
| Ardelyx, Inc. | 9 | $272 |
| AstraZeneca | 11 | $253 |
| Vifor Pharma, Inc. | 8 | $215 |
| Amgen | 6 | $183 |
| Otsuka America Pharmaceutical, Inc. | 4 | $122 |
| Aurinia Pharma U.S., Inc. | 3 | $79 |
| Fresenius USA Marketing, Inc. | 4 | $77 |
| Boehringer Ingelheim | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $21 |
| Insulet Corporation | 1 | $20 |
| Novartis | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$737
- XPHOZAH 30 MG$123
- Vafseo$122
How this compares
$8,684 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 46 | $92,090 |
| VeltassaPatiromer Calcium Sorbitex | 66 | $69,047 |
| XphozahTenapanor Hcl | 22 | $67,052 |
| VelphoroSucroferric Oxyhydroxide | 12 | $37,967 |
| OzempicSemaglutide | 32 | $27,220 |
| Sevelamer Carbonate | 106 | $22,346 |
| Lanthanum Carbonate | 41 | $21,451 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $8,643 |
| Clonidine | 20 | $5,402 |
| Calcium Acetate | 44 | $3,915 |
| Nifedipine ErNifedipine | 52 | $2,392 |
| Labetalol Hcl | 11 | $635 |
| Hydralazine Hcl | 27 | $447 |
| Metoprolol Succinate | 22 | $420 |
| Losartan Potassium | 52 | $382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $730 | $92,09046 claims |
| Fresenius USA Marketing, Inc.Velphoro | $77 | $37,96712 claims |
| Novo NordiskOzempic | $21 | $27,22032 claims |
| AstraZenecaLokelma | $253 | $8,64312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.
Other medical in Granada Hills
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.